



MARUTI SUZUKI

Automobiles

Healthy show continues; maintain HOLD on elevated valuations

- Q1 revenue grew 10% YoY driven by demand in SUVs and realisations which improved 5%/4% YoY/QoQ
- Softening commodities costs and healthy volumes helped EBITDA margin expand by 344 bps YoY to 12.7% (+42bps QoQ)
- We value the stock at 25x P/E 1Y forward earnings, on par with its 10Y average, and revise its TP to Rs 13,305 (from Rs 12,965). Retain HOLD

Steady topline growth aided by realisation gains: MSIL's Q1FY25 revenue grew 10.0% YoY (-7.1% QoQ) to Rs 355bn in a challenging quarter. This was backed by 5% YoY volume gains (-10.6% QoQ) and realisation improvement of 5%/4% YoY/QoQ. Higher SUV demand continued to drive sales volume of 521.8k units. Average blended realisation/vehicle was Rs 680.8mn. MSIL extended higher discounts/vehicle for Q1FY25 (Rs 21.7k vs Rs 14.5k in Q4FY24).

Operating margin expands YoY, remained flat QoQ: Raw material cost at 71.4% of sales dropped 262bps YoY and 120bps QoQ, aiding gross margin improvement of 262bps YoY (120bps QoQ) to 29.8%. Other expenditure rose 4.3% YoY (fell 7.3% QoQ) to Rs 45.3bn. Higher sales volume, cost reduction efforts and favourable commodity prices helped EBITDA grow 50.9% YoY to ~Rs 45bn, with margin expansion of 344bps YoY to 12.7% (flat QoQ).

Capacity expansion plans: MSIL commissioned additional facility at Manesar with capacity to manufacture 0.1mn units in Q1FY25, increasing the manufacturing capacity at the Manesar facility to 0.9mn/year. MSIL also increased the capacity of Ertiga and the supply of CNG vehicles. Further, MSIL's planned expansion at Kharkhoda (Haryana) with a capacity of 0.25mn vehicles/p.a. is due to become operational in CY25. MSIL has signed an MoU with the Gujarat government to set up a 1mn unit plant by FY29 and has earmarked Rs 350bn of capex.

Maintain HOLD on steep valuation; estimates unchanged: We maintain our FY25/FY26 EPS, factoring an in-line expected show in Q1FY25. We introduce FY27 earnings with 3Y Revenue/EBITDA/PAT CAGR of 14%/15%/11%. Our gross margin assumptions hover at ~29% with EBITDA margin of ~12% over our forecast period. We factor in upbeat growth outlook backed by MSIL's focus on premiumisation, healthy capex and thrust on electric vehicles (EVs). However, the elevated valuations leave limited room for uptick. Effectively, we maintain our HOLD rating. We continue to value the stock at 25x P/E 1-year forward earnings, on par with its 10Y average, yielding a higher TP of Rs 13,305 (from Rs 12,965).

03 August 2024

Milind Raginwar research@bobcaps.in

Key changes

	Target	Rating			
		<►			
Ticke	er/Price	MSIL IN/Rs 12,726			
Mark	et cap	US\$ 45.9bn			
Free	float	44%			
3M ADV		US\$ 92.8mn			
52wk high/low		Rs 13,680/Rs 9,254			
Prom	noter/FPI/DII	56%/23%/16%			

Source: NSE | Price as of 2 Aug 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Total revenue (Rs mn)	14,09,326	16,28,760	18,47,013
EBITDA (Rs mn)	1,64,011	1,93,512	2,20,664
Adj. net profit (Rs mn)	1,32,094	1,42,362	1,59,169
Adj. EPS (Rs)	437.3	471.3	526.9
Consensus EPS (Rs)	437.3	475.6	531.2
Adj. ROAE (%)	15.8	15.1	14.9
Adj. P/E (x)	29.1	27.0	24.2
EV/EBITDA (x)	23.4	20.3	17.7
Adj. EPS growth (%)	64.1	7.8	11.8
Source: Company, Bloomberg, B	OBCAPS Rese	arch P – Provis	ional

Stock performance



Source: NSE





Fig 1 – Earnings call highlights

Parameter	Q1FY25	Q4FY24	Our view
Volumes	MSIL sold 521.8k vehicles during Q1FY25, 4.8% higher YoY. In Q1FY25, sales from the domestic market stood at 451.3k units, up by 3.8% YoY. In the domestic market, the demand for passenger vehicles (PVs) was muted to some extent, largely due to the heatwave and elections that impacted walk-ins.	Industry growth for passenger vehicles was 8.3% in FY23-24. Hatchback sales were down to 27% from 46% in 2018-19 and steadily replaced by sports utility vehicle (SUV) sales. CNG vehicles accounted for 15% share from 10.4% YoY and hybrid and EV penetration remained at 2% each. Green vehicles grew by 42% compared to 37% YoY. SUVs contributed to over 50% of the market and was the key driver of growth in the passenger vehicle market.	MSIL continues to focus on a favourable mix. In terms of launches, MSIL launched its fourth-generation EPIC New Swift in May'24. Also, MSIL introduced the Dream Series as new offers for potential buyers in the small car segment. The revival in first- time users and rural demand will aid lower-end demand too.
Margins	In Q1FY25, marginal benefits from commodities and products offsets the increased discounts. Operating income contributed 70bps to margin expansion which includes staff sales, extended warranty income from business, etc. Manufacturing and admin expenses contributed 30bps to margin expansion. Reduction in volume by 10.5%, i.e, 521.8k in Q1FY25 from 584.0k in Q4FY24, had a negative impact of 80bps on operating leverage.	EBITDA margin had limited traction of ~60bps QoQ despite a 50bps price hike and discounts lower by 140bps cumulatively having ~200bps benefit including forex gains. This was largely due to commodity price inflation of 20bps, product mix and constraints in CNG supplies. Margins improved sharply YoY.	Mild reversal in commodity prices and component shortage of CNG vehicles may impact margins in the short term. However, an increasing share of high-end products will help MSIL retain better product mix and, hence, gross/EBITDA margins.
Discounts	Discounts extended per vehicle for Q1FY25 were at Rs 21.7k compared to Rs 14.5k in Q4FY24.	Discounts offered at retail sales were Rs 18.0k.	Better raw material cost mix helped offset the higher discount impact.
Supply	MSIL increased production capacity of Ertiga as it had a high CNG percentage. MSIL increased the supply of CNG vehicles too.	Certain components in CNG vehicles were in short supply in 4QFY24 which impacted CNG sales at 27%, lower than the 30.2% QoQ.	With limited supply-side constraints in the near future, growth will be more secure.
Order book	MSIL has indicated 0.6mn CNG car units for FY25. In Q1FY25, MSIL achieved slightly less than 0.15mn units.	Total pending order book was 0.2mn units, unchanged QoQ. Of the pending order book 0.11mn units were for CNG variants with the bulk outstanding for the Ertiga model.	The capacity addition at Manesar should address the Ertiga waiting period, in our view.
Commodities	Gross margins on a QoQ basis improved 90bps, of which 60bps was one-off. Effectively only 30bps improvement was seen as key commodities like steel remained favourable to the extent of about Rs 2.5/kg when compared with Q4FY24 to Q1FY25.	Copper and aluminium prices are likely to inflate (copper/aluminum are 1%/3% of MSIL's net sales). Steel exposure is about ~11% of net sales and hardening in 1QFY25. Platinum, palladium, rhodium are ~2.5% of sales and are softening.	Some negative surprises may be stored in due to commodity cost inflation in the near term.
Capacity	In Q1FY25, MSIL commissioned an additional facility at Manesar with the capacity to manufacture 0.1mn units. With this the total manufacturing capacity at the Manesar facility will be 0.9mn per annum.	Management has targeted the increase of annual sales to 4mn units by FY31. Kharkhoda plant with an operational capacity of ~0.25mn units is expected to be operational in CY25 and pace up to four plants of similar size at the same location, taking the capacity to 1mn units. The capacity addition at Manesar should address the demand for Ertiga. MSIL has signed an MoU with the Gujarat government to set up a manufacturing facility with an annual capacity of 1mn units in the state to be operational by FY29.	Capacity expansion is key for growth and is being addressed by management. MSIL's focus on the EV segment is a step in the right direction.



Parameter	Q1FY25	Q4FY24	Our view
Exports	Sales volume in the export market was ~70.56K units, growth of 11.6% YoY from 1QFY24. MSIL had 40% of share in India's total passenger vehicle exports in Q1FY25. The royalty payment stayed at 3.5% of sales.	Sales volume in the export market was ~78k units, growth of 21.7% YoY in 4Q. Exports were 13% of total sales in FY24. MSIL plans to export 0.3mn units in FY25.	Exports still form a relatively small proportion of the topline. Steady exports demand will aid revenue growth.
Electric Vehicles	MSIL will display its EV Model at the motor show, the auto expo or the Bharat Mobility Show in Jan'25. MSIL has six electric vehicle (EV) models lined up till 2031 and plans to launch one EV model every year. MSIL has guided for 0.6mn CNG car units for FY25. In Q1FY25, MSIL achieved slightly less than 0.15mn units.	MSIL is on track to commence EV production in CY24. Despite a change in the global scenario for EVs, MSIL will not change launch timings. MSIL would like to have more hybrid models depending on CO2 emissions, customer acceptance, volume, viability, and new technology absorption.	This is in line with the company's long-term guidance of launching EVs by FY25-end.
Other key points	MSIL aims to maintain inventory level of around 30 days. At the end of Q1FY25, the company's inventory level stood at 37 days but it expects levels to be manageable going forward.	Management suggested 0.13mn units inventory by end-FY24, implying one month inventory with dealers. However, this is unhealthy as this implies at least one variant will be absent with the showroom/dealership. But with the increased sales volume one month of inventory will be the new norm.	No major concerns over maintaining marginally higher inventory as this will be reversed in the festive season.

Source: Company, BOBCAPS Research

(Rs mn)	1QFY25	1QFY24	YoY (%)	4QFY24	QoQ (%)
Volume (units)	5,21,868	4,98,030	4.8	5,84,031	(10.6)
Avg. Realisation per Vehicle (Rs)	6,80,850	6,49,095	4.9	6,54,672	4.0
Net Revenues	3,55,314	3,23,269	9.9	3,82,349	(7.1)
Total Income (A)	3,55,314	3,23,269	9.9	3,82,349	(7.1)
Operating Expenses:					
Raw materials consumed	2,49,329	2,35,317	6.0	2,72,884	(8.6)
Employee Expenses	15,576	14,609	6.6	13,662	14.0
Other Expenses	45,386	43,513	4.3	48,953	(7.3)
Total Expenditure (B)	3,10,291	2,93,439	5.7	3,35,499	(7.5)
EBITDA (A-B)	45,023	29,830	50.9	46,850	(3.9)
Other Income	9,751	10,012	(2.6)	11,180	(12.8)
Depreciation	7,310	7,475	(2.2)	7,290	0.3
EBIT	47,464	32,367	46.6	50,740	(6.5)
Finance Costs	573	465	23.2	762	(24.8)
PBT after excep items	46,891	31,902	47.0	49,978	(6.2)
Tax expense	10,392	7,051	47.4	11,200	(7.2)
Reported PAT	36,499	24,851	46.9	38,778	(5.9)
Adjusted PAT	36,499	24,851	46.9	38,778	(5.9)
Adj EPS (Rs)	120.9	82.3	46.9	128.4	(5.9)
Key Ratios (%)			(bps)		(bps)
Gross Margin	29.8	27.2	262	28.6	120
EBITDA Margin	12.7	9.2	344	12.3	42
EBIT Margin	13.4	10.0	335	13.3	9
PBT Margin	13.2	9.9	333	13.1	13
Tax Rate	22.2	22.1	6	22.4	(25)
Adj PAT Margin	10.3	7.7	258	10.1	13

Source: Company, BOBCAPS Research



Valuation methodology

We maintain our FY25/FY26 EPS factoring in the in-line showing expected for Q1FY25. We introduce FY27E earnings with 3Y Revenue/EBITDA/PAT CAGR of 14%/15%/11%. Our gross margin assumptions hover at ~29% with EBITDA margin of ~12% over our forecast period. We factor in an upbeat growth outlook backed by MSIL's focus on premiumisation, healthy capex and thrust on electric vehicles. However, the elevated valuations leave limited room for uptick.

Effectively, we maintain our HOLD rating. We continue to value the stock at 25x P/E 1year forward earnings, on par with its 10Y average, yielding a revised TP of Rs 13,305 (from Rs 12,965).

Fig 3 – Revised estimates

(Do mm)		New			Old		(Change (%)	
(Rs mn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	16,28,760	18,47,013	21,09,058	16,28,760	18,47,013	NA	(0.0)	0.0	NA
EBITDA	1,93,512	2,20,664	2,47,052	1,93,512	2,20,664	NA	0.0	0.0	NA
Adj PAT	1,42,362	1,59,169	1,78,419	1,42,666	1,59,785	NA	(0.2)	(0.4)	NA
Adj EPS (Rs)	471.3	526.9	590.6	472.3	528.9	NA	(0.2)	(0.4)	NA

Source: BOBCAPS Research

Fig 4 – Key assumptions

Parameter	FY24P	FY25E	FY26E	FY27E
Volume (nos)	20,64,472	23,27,502	25,13,702	27,33,651
ASP (Rs)	6,66,465	6,99,789	7,34,778	7,71,517
Revenues (Rs mn)	14,09,326	16,28,760	18,47,013	21,09,058
EBITDA (Rs mn)	1,64,011	1,93,512	2,20,664	2,47,052
Operating margin (%)	11.6	11.9	11.9	11.7
Adjusted Net Profit (Rs mn)	1,32,094	1,42,362	1,59,169	1,78,419
Adjusted EPS (Rs)	437	471	527	591

Source: Company, BOBCAPS Research

Fig 5 – Peer comparison

Company	Ticker Rating		Target Price	EPS (Rs)		ROE (%)	
Company	Ticker	Rating	(Rs)	FY25E	FY26E	FY25E	FY26E
Maruti Suzuki	MSIL IN	HOLD	13,305	471.3	526.9	16	15.8
Mahindra & Mahindra	MM IN	BUY	3,279	100.1	118.8	21.1	21.1
Tata Motors	TTMT IN	NOT RATED	-	66.5	80.1	25.9	24.4

Source: BOBCAPS Research







Fig 6 – P/E band: We value MSIL at 25x 1-year forward EPS

Fig 7 – P/E 1Y fwd: The valuation is at mean average



Source: Company, Bloomberg, BOBCAPS Research

Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key upside/downside risks to our estimates are:

- intense competitive pressure leading to irrational price cuts,
- commodity inflation subsiding faster than expected, and
- delays in model launches in various segments, including CNG and electric vehicles.



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24P	FY25E	FY26E	FY27E
Total revenue	11,75,229	14,09,326	16,28,760	18,47,013	21,09,058
EBITDA	1,10,077	1,64,011	1,93,512	2,20,664	2,47,052
Depreciation	28,233	30,223	37,158	43,682	48,926
EBIT	1,03,457	1,72,336	1,84,164	2,08,544	2,33,706
Net interest inc./(exp.)	(1,866)	(1,932)	(1,649)	(1,831)	(1,239)
Other inc./(exp.)	21,613	38,548	27,810	31,561	35,581
Exceptional items	0	0	0	0	0
EBT	1,01,591	1,70,404	1,82,515	2,06,713	2,32,467
Income taxes	21,099	38,310	40,153	47,544	54,049
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	80,492	1,32,094	1,42,362	1,59,169	1,78,419
Adjustments	0	0	0	0	0
Adjusted net profit	80,492	1,32,094	1,42,362	1,59,169	1,78,419

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY23A	FY24P	FY25E	FY26E	FY27E
Accounts payables	1,51,982	1,73,677	2,06,574	2,36,207	2,69,719
Other current liabilities	27,163	43,890	44,247	52,627	60,944
Provisions	10,500	13,514	14,865	16,352	17,987
Debt funds	38,322	31,947	33,532	24,025	17,275
Other liabilities	0	0	0	0	0
Equity capital	1,510	1,572	1,510	1,510	1,510
Reserves & surplus	6,02,311	8,35,227	9,44,375	10,65,040	11,98,902
Shareholders' fund	6,03,821	8,36,799	9,45,885	10,66,550	12,00,412
Total liab. and equities	8,31,788	10,99,827	12,45,103	13,95,761	15,66,337
Cash and cash eq.	377	1,579	16,652	21,074	39,835
Accounts receivables	32,958	46,013	40,719	47,099	53,781
Inventories	42,838	41,196	65,150	74,804	85,417
Other current assets	55,324	62,190	70,721	78,192	86,184
Investments	4,77,564	6,85,137	7,41,015	8,37,015	9,42,015
Net fixed assets	1,78,938	1,96,580	2,29,422	2,45,741	2,56,815
CWIP	28,081	53,712	65,000	75,000	85,000
Intangible assets	0	0	0	0	0
Deferred tax assets, net	3,411	1,124	4,127	4,540	4,994
Other assets	12,296	12,296	12,296	12,296	12,296
Total assets	8,31,787	10,99,827	12,45,103	13,95,761	15,66,337

Cash Flows

FY23A	FY24P	FY25E	FY26E	FY27E
91,473	1,44,994	1,57,475	1,85,453	2,08,702
(68,785)	(73,496)	(81,288)	(70,000)	(70,000)
(69,931)	(2,07,573)	(55,878)	(96,000)	(1,05,000)
21,613	38,548	27,810	31,561	35,581
(1,17,103)	(2,42,521)	(1,09,356)	(1,34,439)	(1,39,419)
0	62	(62)	0	0
12,322	(6,375)	1,585	(9,506)	(6,750)
(1,866)	(1,932)	(1,649)	(1,831)	(1,239)
(18,125)	(27,187)	(39,300)	(44,802)	(51,074)
(1,384)	2,287	(3,003)	(413)	(454)
(9,053)	(33,145)	(42,429)	(56,552)	(59,517)
(34,683)	(1,30,672)	5,689	(5,539)	9,765
377	1,579	16,652	21,074	39,835
	91,473 (68,785) (69,931) 21,613 (1,17,103) 0 12,322 (1,866) (18,125) (1,384) (9,053) (34,683)	91,473 1,44,994 (68,785) (73,496) (69,931) (2,07,573) 21,613 38,548 (1,17,103) (2,42,521) 0 62 12,322 (6,375) (1,866) (1,932) (18,125) (27,187) (1,384) 2,287 (9,053) (33,145) (34,683) (1,30,672)	91,473 1,44,994 1,57,475 (68,785) (73,496) (81,288) (69,931) (2,07,573) (55,878) 21,613 38,548 27,810 (1,17,103) (2,42,521) (1,09,356) 0 62 (62) 12,322 (6,375) 1,585 (1,866) (1,932) (1,649) (18,125) (27,187) (39,300) (1,384) 2,287 (3,003) (9,053) (33,145) (42,429) (34,683) (1,30,672) 5,689	91,473 1,44,994 1,57,475 1,85,453 (68,785) (73,496) (81,288) (70,000) (69,931) (2,07,573) (55,878) (96,000) 21,613 38,548 27,810 31,561 (1,17,103) (2,42,521) (1,09,356) (1,34,439) 0 62 (62) 0 12,322 (6,375) 1,585 (9,506) (1,866) (1,932) (1,649) (1,831) (18,125) (27,187) (39,300) (44,802) (1,384) 2,287 (3,003) (413) (9,053) (33,145) (42,429) (56,552) (34,683) (1,30,672) 5,689 (5,539)

Y/E 31 Mar (Rs)	FY23A	FY24P	FY25E	FY26E	FY27E
Reported EPS	266.5	437.3	471.3	526.9	590.6
Adjusted EPS	266.5	437.3	471.3	526.9	590.6
Dividend per share	60.0	90.0	130.1	148.3	169.1
Book value per share	1,998.9	2,770.1	3,131.2	3,530.7	3,973.8
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24P	FY25E	FY26E	FY27E
EV/Sales	3.2	2.7	2.4	2.1	1.8
EV/EBITDA	34.6	23.4	20.3	17.7	15.5
Adjusted P/E	47.8	29.1	27.0	24.2	21.5
P/BV	6.4	4.6	4.1	3.6	3.1
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24P	FY25E	FY26E	FY27
Tax burden (Net profit/PBT)	79.2	77.5	78.0	77.0	76.
Interest burden (PBT/EBIT)	98.2	98.9	99.1	99.1	99.
EBIT margin (EBIT/Revenue)	8.8	12.2	11.3	11.3	11.
Asset turnover (Rev./Avg TA)	194.4	186.6	176.3	178.5	182.
Leverage (Avg TA/Avg Equity)	1.1	1.0	1.0	1.0	1.
Adjusted ROAE	14.1	18.3	16.0	15.8	15.
Derite A set of					
Ratio Analysis Y/E 31 Mar	FY23A	FY24P	FY25E	FY26E	FY27
YoY growth (%)					
Revenue	33.1	19.9	15.6	13.4	14.
EBITDA	93.1	49.0	18.0	14.0	12.
Adjusted EPS	113.7	64.1	7.8	11.8	12.
Profitability & Return ratios (%)					
EBITDA margin	9.4	11.6	11.9	11.9	11.
EBIT margin	8.8	12.2	11.3	11.3	11.
Adjusted profit margin	6.8	9.4	8.7	8.6	8.
Adjusted ROAE	14.1	15.8	15.1	14.9	14.
ROCE	13.5	17.4	15.2	15.2	15.
Working capital days (days)					
Receivables	8	10	10	9	
Inventory	12	11	12	14	1
Payables	60	59	60	62	6
Ratios (x)					
Gross asset turnover	0.3	0.3	0.3	0.3	0.
Current ratio	0.7	0.7	0.7	0.7	0.0
Current ratio	0.1	•	•	••••	
Net interest coverage ratio	(55.4)	(89.2)	(111.7)	(113.9)	(188.6

Source: Company, BOBCAPS Research | Note: TA = Total Assets



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): MARUTI SUZUKI (MSIL IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

MARUTI SUZUKI



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.